Abstract
Parkinsons disease (PD) is a neurodegenerative disorder of central nervous system (CNS) that impaired the patient motor skills, speech and other functions. Adenosine A2A receptors have a unique cellular distribution in the neuron, which is used as a potential target for PD. Homology modeling was used to construct the 3-D structure of A2A using the known template (PDB: 2VT4), and the stereochemical quality was validated. Several effective antagonist drugs were selected and active amino acid residues in A2A were targeted on the basis of robust binding affinity between proteindrug interactions in molecular docking. Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor. It could be used as the basis for rationale designing of novel antagonist drugs against Parkinsons diseas.
Keywords: Adenosine A2A, Parkinson's disease, antagonists, homology modeling, docking
Current Aging Science
Title: Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Volume: 2 Issue: 2
Author(s): Vijai Singh and Pallavi Somvanshi
Affiliation:
Keywords: Adenosine A2A, Parkinson's disease, antagonists, homology modeling, docking
Abstract: Parkinsons disease (PD) is a neurodegenerative disorder of central nervous system (CNS) that impaired the patient motor skills, speech and other functions. Adenosine A2A receptors have a unique cellular distribution in the neuron, which is used as a potential target for PD. Homology modeling was used to construct the 3-D structure of A2A using the known template (PDB: 2VT4), and the stereochemical quality was validated. Several effective antagonist drugs were selected and active amino acid residues in A2A were targeted on the basis of robust binding affinity between proteindrug interactions in molecular docking. Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor. It could be used as the basis for rationale designing of novel antagonist drugs against Parkinsons diseas.
Export Options
About this article
Cite this article as:
Singh Vijai and Somvanshi Pallavi, Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease, Current Aging Science 2009; 2 (2) . https://dx.doi.org/10.2174/1874609810902020127
DOI https://dx.doi.org/10.2174/1874609810902020127 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Distribution of Quercetin in Different Organs of Male Sprague Dawley Rats Under Hypoxia: A High-Performance Thin Layer Chromatography Approach
Current Chromatography Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Histone Deacetylase Inhibitors: A Novel Therapeutic Approach to Huntingtons Disease (Complex Mechanism of Neuronal Death).
Current Alzheimer Research JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Withanolides: Biologically Active Constituents in the Treatment of Alzheimer’s Disease
Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology